HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eiichi Araki Selected Research

(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acid

9/2021Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
1/2021Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
11/2019Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
2/2019Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
1/2019Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
11/2018Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
9/2018Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
6/2018Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
1/2018Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
1/2018Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eiichi Araki Research Topics

Disease

39Type 2 Diabetes Mellitus (MODY)
09/2022 - 09/2002
26Insulin Resistance
04/2022 - 04/2005
19Hyperglycemia
03/2016 - 02/2002
18Hypoglycemia (Reactive Hypoglycemia)
04/2022 - 01/2003
11Body Weight (Weight, Body)
09/2022 - 03/2014
11Obesity
10/2020 - 07/2007
11Atherosclerosis
01/2019 - 10/2004
10Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2021 - 04/2002
8Neoplasms (Cancer)
04/2021 - 12/2002
7Dyslipidemias (Dyslipidemia)
09/2021 - 06/2011
7Diabetes Complications
01/2016 - 01/2006
6Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
01/2021 - 04/2002
6Hypertension (High Blood Pressure)
01/2021 - 12/2002
6Inflammation (Inflammations)
01/2020 - 04/2010
5Diabetes Mellitus
04/2021 - 04/2002
5Hypertriglyceridemia
01/2021 - 01/2018
5Diabetic Nephropathies (Diabetic Nephropathy)
06/2017 - 10/2003
4Glucose Intolerance
08/2018 - 12/2007
4Drug-Related Side Effects and Adverse Reactions
06/2018 - 01/2016
3Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2021 - 11/2010
3Fatty Liver
05/2021 - 04/2014
3Hyperaldosteronism (Conn Syndrome)
01/2020 - 01/2012
3Weight Loss (Weight Reduction)
03/2019 - 10/2010
3Polyuria
03/2019 - 10/2010
3Atherosclerotic Plaque (Atheroma)
01/2019 - 01/2012
3Weight Gain
11/2016 - 01/2013
3Diabetic Retinopathy (Retinopathy, Diabetic)
07/2012 - 05/2003
3Hypercholesterolemia
03/2012 - 06/2011
3Cushing Syndrome
01/2012 - 12/2002
3Diabetic Angiopathies (Diabetic Angiopathy)
06/2010 - 09/2007
2SHORT syndrome
04/2022 - 02/2022
2Pituitary Neoplasms (Pituitary Adenoma)
04/2021 - 11/2018
2Hypokalemia
03/2019 - 01/2010
2Papillary Thyroid Cancer
11/2018 - 01/2016
2Stroke (Strokes)
01/2014 - 07/2005
2Cardiovascular Diseases (Cardiovascular Disease)
09/2012 - 01/2012

Drug/Important Bio-Agent (IBA)

45Insulin (Novolin)FDA Link
04/2022 - 02/2002
35Glucose (Dextrose)FDA LinkGeneric
09/2022 - 01/2003
11Reactive Oxygen Species (Oxygen Radicals)IBA
01/2021 - 01/2003
10(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
09/2021 - 01/2018
10Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2020 - 05/2006
9Blood Glucose (Blood Sugar)IBA
09/2022 - 01/2003
8dapagliflozinIBA
01/2021 - 07/2016
6Triglycerides (Triacylglycerol)IBA
09/2022 - 06/2011
6Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2019 - 05/2007
6LipidsIBA
01/2019 - 03/2012
6Hormones (Hormone)IBA
11/2013 - 12/2002
5Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021 - 05/2007
5Hypoglycemic Agents (Hypoglycemics)IBA
12/2019 - 10/2005
5Hydrocortisone (Cortisol)FDA LinkGeneric
01/2013 - 12/2002
4SodiumIBA
09/2022 - 03/2014
4Insulin ReceptorIBA
04/2022 - 03/2005
4Superoxide DismutaseIBA
01/2021 - 01/2006
4AldosteroneIBA
01/2020 - 01/2010
4insulin degludecIBA
12/2019 - 09/2016
4Metformin (Glucophage)FDA LinkGeneric
12/2019 - 01/2006
4CytokinesIBA
11/2014 - 06/2003
4AdiponectinIBA
11/2014 - 07/2007
4AMP-Activated Protein KinasesIBA
06/2010 - 01/2006
3Sodium-Glucose Transporter 2 InhibitorsIBA
09/2022 - 03/2014
3AutoantibodiesIBA
04/2022 - 04/2002
3semaglutideIBA
12/2021 - 01/2018
3AlbuminsIBA
01/2021 - 05/2003
3Dipeptidyl-Peptidase IV InhibitorsIBA
01/2021 - 02/2013
3Fatty Acids (Saturated Fatty Acids)IBA
01/2021 - 07/2007
3ReninIBA
01/2020 - 01/2010
3Interleukin-6 (Interleukin 6)IBA
05/2019 - 02/2010
3Pioglitazone (Actos)FDA Link
01/2019 - 01/2009
3Apolipoproteins E (ApoE)IBA
01/2019 - 02/2009
3Fenofibrate (CiL)FDA LinkGeneric
06/2018 - 01/2016
3AdipokinesIBA
11/2014 - 02/2010
3Messenger RNA (mRNA)IBA
02/2013 - 10/2003
3Adrenocorticotropic Hormone (ACTH)FDA Link
01/2012 - 12/2002
3HSP72 Heat-Shock ProteinsIBA
07/2011 - 01/2008
3PPAR gammaIBA
08/2010 - 04/2005
38-Hydroxy-2'-DeoxyguanosineIBA
06/2010 - 09/2007
2B-insulinIBA
04/2022 - 02/2022
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
04/2022 - 02/2022
2Lipoproteins (Lipoprotein)IBA
09/2021 - 06/2011
2Biomarkers (Surrogate Marker)IBA
05/2021 - 05/2003
2Biological ProductsIBA
10/2020 - 08/2008
2Nonesterified Fatty Acids (NEFA)IBA
10/2020 - 02/2013
2LinagliptinIBA
01/2020 - 10/2019
2oxidized low density lipoproteinIBA
11/2019 - 10/2004
2Insulin Glargine (Lantus)FDA Link
08/2019 - 09/2016
2Glucagon-Like Peptide 1 (GLP 1)IBA
05/2019 - 02/2013
2Octreotide (Sandostatin)FDA LinkGeneric
11/2018 - 10/2005
2Proteins (Proteins, Gene)FDA Link
08/2018 - 10/2003
2ApolipoproteinsIBA
01/2018 - 08/2010
2BiguanidesIBA
12/2016 - 02/2013
2C-Reactive ProteinIBA
11/2014 - 04/2010
2Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2014 - 11/2010
2glimepiride (Amarel)FDA LinkGeneric
05/2014 - 01/2013
2Sitagliptin Phosphate (Januvia)FDA Link
05/2014 - 01/2013
26- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
04/2014 - 03/2014

Therapy/Procedure

26Therapeutics
01/2021 - 09/2002
13Glycemic Control
04/2021 - 01/2003
3Drug Therapy (Chemotherapy)
01/2017 - 02/2013
3Exercise Therapy (Therapy, Exercise)
01/2017 - 03/2014
2Injections
01/2015 - 01/2013